Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Pain. 2020 Jun;161(6):1381–1398. doi: 10.1097/j.pain.0000000000001818

Figure 5. Ld-IL2 treatment increases the number of Treg cells in dura and TG.

Figure 5.

(A) Representative images of EGFP+ Treg cells and CD3+ cells in the dura of DEREG mice that received repeated NTG and/or ld-IL2 administrations. Arrowheads indicate double-labeled CD3+EGFP+ Treg cells.

(B-C) Daily ld-IL2 treatment (x 15 days) significantly increases the number of EGFP+ Treg cells (B) and the frequency of EGFP+ Treg among CD3+ T cells (C) in the dura surrounding the MMA of male DEREG mice (n = 3/group). **p < 0.01, **p < 0.001, two-way ANOVA with post hoc Bonferroni test.

(D) Representative images of EGFP+ Treg cells in the TG of DEREG mice that received repeated NTG and/or ld-IL2 administrations.

(E) Daily ld-IL2 treatment (x 15 days) significantly increases the number of EGFP+ Treg cells in the TG of female DEREG mice (n = 5 and 4 mice in vehicle+IL2 and NTG+IL2 groups; vehicle+saline and NTG+saline groups: same mice as in Fig. 1F). **p < 0.01, ***p < 0.001, two-way ANOVA with post hoc Bonferroni test.

(F) Daily ld-IL2 treatment (x 15 days) significantly increases the number of EGFP+ Treg cells in the DRG of male DEREG mice (n = 6/group). **p < 0.01, two-tailed t-test.